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Abstract
Background and purpose We investigated the acute toxicity of accelerated partial breast irradiation using external beam 
(EB-APBI) or intraoperative radiotherapy (IORT) techniques in elderly breast cancer patients.
Materials and methods Women ≥ 60 years with unifocal breast tumors of ≤ 30 mm were eligible for this prospective multi-
center cohort study. IORT was applied with electrons following lumpectomy (23.3 Gy). EB-APBI was delivered using 
3D-CRT or IMRT in 10 daily fractions of 3.85 Gy within 6 weeks after surgery. Acute toxicity was scored using the CTCAE 
v3.0 at 3 months after treatment. Patient-reported symptoms were analyzed using visual analogue scales (VAS) for pain and 
fatigue (scale 0–10), and single items from the EORTC QLQ-C30 and Breast Cancer questionnaires.
Results In total, 267 (IORT) and 206 (EB-APBI) patients were available for toxicity analysis. More patients experi-
enced ≥ grade 2 CTCAE acute toxicity in the IORT group (10.4% IORT and 4.9% EB-APBI; p = 0.03); grade 3 toxicity was 
low (3.3% IORT and 1.5% EB-APBI; ns); and no grade 4 toxicity occurred. EB-APBI patients experienced less fatigue direct 
postoperatively (EORTC p < 0.00, VAS p < 0.00). After 3 months only pain, according to the VAS scale, was significantly 
worse in the EB-APBI group (p < 0.00).
Conclusion Acute toxicity after IORT and EB-APBI treatment is acceptable.
Keywords Elderly · Early-stage breast cancer · Accelerated partial breast irradiation · Intraoperative radiotherapy · Acute 
toxicity
Introduction
Adjuvant whole breast irradiation (WBI) has shown to pre-
vent local recurrence when administered as part of breast 
conserving therapy (BCT) for early-stage breast cancer 
patients [1–3]. However, WBI is inevitably associated 
with a significant treatment burden for the patient, given 
the number of fractions needed. Compliance to treatment is 
often suboptimal, especially for patients living further away 
from a radiation center [4, 5]. In addition, WBI can cause 
considerable damage to normal tissue resulting in fibrosis 
and skin toxicity [6]. Accelerated partial breast irradiation 
(APBI) encompasses the irradiation of solely the tumor bed, 
as recurrences most often occur in this area. This allows a 
higher dose per fraction and a shorter treatment duration 
while sparing healthy tissue. APBI has been studied elabo-
rately over the past decades with several randomized tri-
als proving similar tumor control after 5 years for APBI 
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compared to WBI in selected patients [7–11]. GEC-ESTRO 
and ASTRO have provided guidelines for treatment selection 
for patients eligible for APBI inside and outside of clinical 
trials [12, 13].
APBI can be delivered with various techniques: intra-
operative using either electrons or photons, externally or 
with brachytherapy. With IORT, by applying a single dose 
of radiotherapy to the tumor bed directly after lumpectomy, 
irradiation of the skin is avoided. Results regarding toxicity 
of electron IORT are scarce, but show less skin toxicity for 
IORT [10]. More data on toxicity are available for intraop-
erative radiotherapy using photons, but this technique differs 
substantially from electron IORT and this plausibly trans-
lates into different side effects [8]. For external beam APBI 
(EB-APBI), in which the skin still receives a significant dos-
age, the results regarding acute toxicity are variable [14–17].
More data on toxicity and safety of the different treat-
ment options are important for patients eligible for APBI, as 
well as physicians considering to offer APBI as a treatment 
option for elderly patients. We set up a prospective cohort 
study of elderly (≥ 60 years) patients treated with either 
electron IORT or EB-APBI. In this analysis, we will report 




This prospective cohort study opened in 2011 in two par-
ticipating centers initially: the Haaglanden Medical Center 
where patients were included to be treated with IORT, and 
the Haga Hospital where patients were included to be treated 
with EB-APBI. In 2015, a third center joined; the Isala in 
Zwolle accrued patients for the EB-APBI cohort. Inclusion 
was complete in November 2016. This was a non-rand-
omized study; eligible patients received treatment accord-
ing to center of inclusion. Inclusion criteria were identical 
for both cohorts.
Female patients aged 60 years or older, with invasive or 
in situ breast tumors of ≤ 30 mm (T1 and any hormonal 
receptor status or T2 and ER/PR positive and Her2neu nega-
tive), and clinical N0 status eligible for BCT and sentinel 
node procedure were eligible for this study. Exclusion cri-
teria were multicentric or multifocal (> 2 cm from index 
lesion) tumors, extensive intraductal carcinoma or lympho-
vascular invasion, positive surgical margins, > pN1a after 
sentinel node procedure (or a positive sentinel node periop-
eratively in the case of IORT), neoadjuvant chemotherapy, 
previous malignancy in the past 5 years, or previous radio-
therapy on the ipsilateral breast. These criteria correspond 
to patients classified as low or intermediate risk according 
to the 2010 GEC-ESTRO recommendations [13]. The 
study was approved by the medical ethical committee (10-
042 METC ZuidwestHolland; NTR2931); patients accepted 
the study by signing informed consent.
Surgery
Lumpectomy was performed either by palpation or localiza-
tion procedure. A tumor-free margin was recommended and 
confirmed by specimen radiology. In the IORT group, perio-
perative visual inspection by a pathologist (IORT) was also 
performed. If the tumor-free resection margin was < 2 mm, 
an additional margin was removed directly by the surgeon. If 
both tumor margins and sentinel node were found to be neg-
ative by perioperative pathology, IORT was administered.
Gold (EB-APBI) or titanium (IORT) markers were 
applied for later identification of the lumpectomy cavity. 
Surgery was performed according to at least level 1 onco-
plastic surgery principles [18]. In general, patients treated 
with IORT received prophylactic antibiotics preoperatively, 
in EB-APBI patients this was administered according to 
local protocol.
Radiotherapy
IORT was administered directly after lumpectomy using an 
IORT dedicated mobile accelerator (Mobetron, INTRAOP, 
USA). A protection disc was placed under the lumpectomy 
site to protect the pectoral muscle, underlying ribs, and 
thoracic cavity. The electron tube diameter covered a total 
of 20 mm laterally of the lumpectomy cavity or clips, and 
ranged from 4 to 6.5 cm with a majority of 5 cm tubes used 
(41%). High-energy electron (6–12 MeV) beam radiotherapy 
was administered, delivering a total dose of 23.3 Gy (pre-
scribed at the 100% isodose, according to ICRU 71) to the 
lumpectomy cavity. The electron energy was sufficient to 
apply 21 Gy at the 90% isodose for the full thickness of the 
glandular tissue.
EB-APBI was delivered within 6 weeks after surgery, in 
10 daily fractions of 3.85 Gy using either Intensity Modu-
lated Radiotherapy (n = 53) or 3D-Conformal Radiotherapy 
(n = 153). The CTV was defined as the region between the 
gold markers and seroma cavity added together, with an 
additional margin of 15 mm minus the lowest tumor-free 
resection margin. A CTV-PTV margin of 9 mm was used, 
excluding the skin.
Organs at risk were contoured, comprising both breasts, 
both lungs, the heart, the thoracic wall (ribs and muscula-
ture), and the skin. The dose was prescribed according to the 
ICRU 50 criteria. At least 98% of the PTV received ≥ 95% 
of the prescribed dose.
The treatment plans were carried out with 2–5 fields 
through use of  ≥  4 MV photons. To ensure quality of 
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positioning, an online position verification procedure on 
the gold markers with Electronic Portal Images was used. 
Patients could be included only if ≤ 35% of the breast 
volume received 100% of the prescribed dose; if this was 
exceeded, patients were technically ineligible for EB-APBI.
Adjuvant therapy
Patients received adjuvant treatment consisting of hormo-
nal or chemotherapy according to the current Dutch breast 
cancer guidelines [19].
Outcomes
Physician-reported toxicity was scored prospectively at a 
3-month follow-up visit. The worst experienced toxicity up 
till 3 months after radiotherapy treatment was scored on a 
5-point scale (none—slight—moderate—severe—surgery) 
regarding postoperative bleeding, hematoma, wound dehis-
cence, seroma, and infection. As this classification devi-
ated from the prespecified CTCAE v3.0, we retrospectively 
scored toxicity according to the CTCAEv3.0 (Appendix 1) 
[20]. This was done by a blinded researcher with a medical 
background and checked by a blinded radiation oncologist 
for all patients with toxicities documented prospectively as 
“moderate” or worse.
Additionally patient-reported toxicity up till 3 months 
after treatment was analyzed. Patients were asked to fill out 
quality of life questionnaires at different time points: preop-
eratively, within 3 weeks after surgery, within 3 weeks after 
the last fraction of radiotherapy (for the EB-APBI cohort), 
and 3 months after either IORT or the last radiotherapy 
fraction. We analyzed six single questions of the EORTC 
QLQ30 and BR23 questionnaires to evaluate the following 
patient-reported symptoms: fatigue, pain, breast pain, swol-
len breast, oversensitive breast, and breast skin side effects. 
Scores of 1–2 (“not at all” and “a little”) were scored nega-
tive, and 3–4 (“quite a bit” and “very much”) were scored 
positive. Patient-reported pain and fatigue as reported on a 
Visual Analogue Scale (VAS) were also analyzed at time 
points after surgery, after EB-APBI and 3 months after radi-
otherapy treatment. Patients scored the amount of burden on 
a continuous scale from 0 till 10, where 0 was no symptoms 
at all and 10 the worst imaginable symptom burden.
Patients analyzed were all patients who had filled out the 
specified questions at the specified time point.
Statistical analysis and study design
Data were collected in  MSAcces® and exported to SPSS 
 23® (IBM SPSS statistics for Windows. Armonk, NY: IBM 
Corp.) for statistical analysis.
This non-randomized prospective cohort study was 
designed as a non-inferiority study with local breast recur-
rence at 5 years as the primary endpoint. Sample size calcu-
lation was done using one proportion non-inferiority power 
analysis. We deemed that local recurrence in this study could 
be 5.7% but should not exceed 10% at 5 years. This resulted 
in a sample size of 179 patients with invasive cancer per 
cohort (IORT and EB-APBI). This sample size provides suf-
ficient power (80%) to detect the difference with a recurrence 
rate after BCT with WBI of 4% per 5 years (α = 0.05). Sam-
ple size was higher due to inclusion of pure DCIS.
Since the IORT cohort reached accrual before the EB-
APBI cohort inclusion to the IORT cohort was continued 
until accrual to the EB-APBI cohort was complete to pre-
vent lag-time bias inclusion. The primary endpoint will be 
reported in the future when follow-up time in both cohorts 
has matured. In this analysis we report acute toxicity, a pre-
specified secondary endpoint.
Patient characteristics in each cohort were described and 
compared using either the Mann–Whitney, independent t test 
or Chi-square test, depending on the type and distribution 
of the data.
Physician-reported toxicity at 3 months was compared 
using the Chi-square test. A two-tailed p value of ≤ 0.05 
was deemed significant for both the patient characteristics 
and toxicity.
Patient-reported toxicity using single questions of the 
EORTC C30 and BR23 questionnaires was compared at the 
different time points between groups using the Chi-square 
test. The VAS scores were compared using the Mann–Whit-
ney test, due to non-normal distribution of data. To correct 
for multiple testing for the patient-reported symptoms, a 
two-tailed p value ≤ 0.01 was used.
Results
Patients
Between January 2011 and November 2016, 316 patients 
entered the IORT treatment cohort and 300 patients the EB-
APBI cohort. Figure 1 shows the patient inclusion flow chart 
for both cohorts.
Eventually 267 patients in the IORT cohort and 206 
patients in the EB-ABPI cohort were eligible for analysis. 
In the IORT cohort 2 patients had bilateral breast cancer 
and both tumors were treated with IORT resulting in 269 
treated tumors in 267 patients. Physician reported toxicity 
was scored separately for each breast tumor.
In Table 1, the patient characteristics of both groups are 
displayed. Median age was 68 and 67 years for the IORT and 
EB-ABPI group, respectively. Most tumors were estrogen 
receptor positive and low-grade (1–2). In 3/269, tumors were 
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proven by preoperative biopsy but no residual tumor bur-
den was found in the lumpectomy specimen (IORT). More 
patients in the IORT group had pN1mi or pN1a tumors.
Only 110/267 (41%) of IORT patients and 77/206 (37%) 
of EB-APBI patients received adjuvant hormonal therapy. 
The percentage of patients receiving chemotherapy alone 
was 1.9% and 2.5, 5.2 and 6% received a combination of 
systemic therapy comprising of CT, HT, and/or trastuzumab 
in the IORT and EB-APBI groups, respectively, according 
to Dutch breast cancer guidelines (19).
Postoperative toxicity
Grade 2 or higher toxicity according to the CTCAE v3.0 
was seen in 10.4% (28/269) of treated breasts in patients 
in the IORT group and in 4.9% (10/206) of patients in the 
EB-APBI group (p = 0.03). Grade 3 toxicity was present in 
3.3% (9/269) of the treated breasts in patients in the IORT 
cohort and 1.5% (3/206) of patients in the EB-APBI cohort 
(p = 0.19). There were no grade 4 complications.
Grade 2 and 3 toxicities per symptom are shown in Fig. 2. 
Different types of toxicity in one patient were scored sepa-
rately. There were significantly more ≥ grade 2 wound infec-
tions in the IORT cohort (7.1% (19/269) IORT, 2.4% (5/206) 
EB-APBI, p = 0.02). Grade 3 wound infections occurred 
in 5/269 of treated breasts in IORT patients, one of which 
was an infection of a mammary prosthesis which had to be 
surgically removed. Two out of 206 patients in the EB-APBI 
cohort experienced grade 3 wound infection, one was treated 
surgically during EB-APBI treatment (radiotherapy was not 
interrupted and the wound closed 2.5 months later), the other 
was treated surgically and the infection resolved before start 
of radiotherapy.
Patient‑reported symptoms
In Fig. 3, patient-reported symptoms for the six prespecified 
EORTC single items are shown. In Appendix 2, patient char-
acteristics of responding patients per time point are shown.
At baseline, 3% more patients reported positive for fatigue 
in the IORT cohort (IORT 29/262, 11.1%; EB-APBI 15/176, 
8.5%). All other symptoms at baseline differed ≤ 0.5% 
between cohorts.
Directly postoperatively, fatigue differed significantly 
between groups with 29.3% (65/222) of patients in the IORT 
group reporting positive for fatigue compared to 16.4% 
(22/134) of patients in the EB-APBI group (p < 0.00). When 
Fig. 1  Patient inclusion flow diagram
553Breast Cancer Research and Treatment (2018) 169:549–559 
1 3
using the VAS scale, fatigue was also significantly worse in 
the IORT patients postoperatively (p < 0.00) (Fig. 4a).
The only patient-reported symptom that increased after 
EB-APBI compared to postoperatively was fatigue (from 
16.4 to 23.9%). All other symptoms, including the VAS 
score for fatigue, either remained the same or decreased.
At 3  months, none of the EORTC patient-reported 
symptoms differed significantly between the two cohorts. 
Although not significant, patients treated with EB-APBI 
reported more Pain (EB-APBI 22/175 12.6%; IORT 24/245 
9.8%; p = 0.37) and Breast pain (EB-APBI 16/175, 8%; 
IORT 14/245, 5.7%, p  =  0.36) after 3  months accord-
ing to the EORTC questionnaires. When asked on a VAS 
scale, EB-APBI patients reported significantly more pain at 
3 months (p < 0.00) (Fig. 4b).
The general tendency of patient-reported symptoms was 
to increase postoperatively and recede towards baseline lev-
els up till 3 months after treatment, with the exception of 
fatigue in the EB-APBI group (Figs. 3, 4).
Discussion
The primary objective of this prospective analysis was to 
evaluate the acute (postoperative) toxicity of two differ-
ent APBI treatment options for early-stage breast cancer 
patients ≥ 60 years. APBI has been extensively studied the 
past decades, but data on acute complications are scarce. 
The prospective evaluation of two different techniques of 
APBI focussing on an elderly patient group makes our study 
unique.
We have established that acute toxicity, postoperatively 
and up till 3 months after treatment, is acceptably low for 
both IORT and EB-APBI. Grade 3 toxicity was especially 
low, and there was no grade 4 toxicity. Directly after surgery 
breast symptoms, pain and fatigue are most prominent, after 
which they gradually decline. Overall, both APBI treatments 
are well tolerated by patients.
In current literature, results regarding toxicity of APBI 
treatments vary [14, 16, 21]. Different tools and alternating 
timings of measurement may explain some of this variation.
Probably even more important, however, is the fact that 
different techniques can be used for APBI, leading to differ-
ent toxicity profiles. In addition, the influence of different 
surgical techniques and systemic therapy on toxicity, treat-
ment compliance, and cosmetic outcome must be taken into 
account [22–24]. Therefore, extrapolating results from one 
type of APBI to another should be done with care.
By evaluating a prospective cohort of early breast cancer 
patients treated with two different types of APBI, we provide 
an overview of acute (postoperative) toxicity for the two 
techniques.
APBI has several benefits that especially facilitate treat-
ment of elderly patients.
Table 1  Patient characteristics
a In the IORT group, 2 patients had  bilateral breast cancer resulting 
in a total of 269 breast tumors treated with IORT. Three patients had 
pT0, biopsy-positive malignancies
IORT, n = 267a EB-APBI, n = 206 p value






 Years 68 59–90 67 59–86 0.683
pT stage
 pTis 18 7% 26 13% 0.068
 pT1a 12 5% 14 7%
 pT1b 80 30% 50 24%
 pT1c 130 49% 89 43%
 pT2 26 10% 27 13%
pN stage (invasive)
 pN0 227 92% 172 96% 0.045
 pN1mi/pN1a 20 8% 6 3%
 unknown 1 0% 2 1%
BR stage (invasive)
 Grade 1 81 33% 61 34% 0.075
 Grade 2 109 44% 91 51%
 Grade 3 56 23% 25 14%
 unknown 2 1% 3 2%
ER (invasive)
 Positive 232 94% 169 94% 0.712
PR (invasive)
 Positive 187 75% 138 78% 0.611
Her2neu (invasive)
 Positive 15 6% 10 6% 0.893
Systemic therapy
 No 157 59% 127 62% 0.538
 HT 91 34% 60 29%
 CT ± HT 19 7% 17 8%
Fig. 2  Toxicity according to CTCAE v3.0, in percentage of patients
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Firstly, APBI shortens treatment duration, an important 
factor for elderly patients as it influences not only patient 
compliance but also treatment choice [25]. Anticipated non-
compliance to radiotherapy is often a reason to either over-
treat, performing mastectomy to avoid irradiation, or under-
treat, applying BCS without irradiation. Both treatments are 
suboptimal, as mastectomy is more mutilating and leads to 
more postoperative complications in elderly patients, espe-
cially in those with comorbidities [26, 27]. Although BCS 
without RT is considered safe in a selected group of elderly 
patients [28], it may lead to a higher local recurrence rate if 
applied to all elderly women [3, 29].
A common symptom related to treatment duration is 
fatigue. In our study, the difference in the course of fatigue 
between IORT and EB-APBI is noteworthy; IORT patients 
are significantly more fatigued after surgery, but EB-APBI 
patients experience increase in fatigue after radiotherapy 
which persists up till 3 months (Figs. 3, 4). Additionally, 
at 3 months, patients who received IORT reported less pain 
than patients treated with EB-APBI.
Secondly, the limited dose to normal tissue will lead to 
reduced toxicity, as compared to WBI. APBI techniques 
facilitate sparing of the skin, and in IORT no skin is irradi-
ated at all. Accordingly, we observed very low skin toxicity, 
with 3% of patients in the IORT cohort and 5% of patients in 
the EB-ABPI cohort reporting skin problems after 3 months. 
In available literature, reported skin toxicity in EB-APBI 
treatment differs, suggesting technique and fractionation 
Fig. 3  Patient-reported symptoms according to EORTC C30 and BR23 single items per time point. Percentage of patients reporting “quite a bit” 
or “very much” bother are shown
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schedule influence skin toxicity [14–16, 21, 30]. Twice 
daily fractionation schedules are often used. However, the 
shortening of the recovery time between radiotherapy frac-
tions might prevent adequate repair of normal tissue thus 
influencing skin toxicity and, in the long term, fibrosis [31]. 
Hence, once daily fractionation of EB-APBI seems prefer-
able regarding skin toxicity.
Even though the irradiated volume using IORT is small, 
we saw more postoperative toxicity in the IORT group com-
pared to EB-APBI. Perhaps the high dose of radiotherapy 
delivered during surgery damages tissue in such a way that it 
augments the chance of other complications such as seroma 
and wound infections. Moreover, with IORT a larger surgical 
bed is created and operation time is prolonged, resulting in a 
higher susceptibility for seroma and wound infections. Still, 
seroma was low in our IORT cohort and similar to seroma 
rates described for other types of IORT [8, 9, 32–35].Timing 
of APBI might also influence postoperative complications. 
In a study where EB-APBI was delivered preoperatively, 
10% of patients developed persistent seroma, 11.4% of 
patients had a postoperative infection, and a total of 16% 
had postoperative complications [36].
One of the disadvantages of IORT may be that additional 
locoregional treatment such as mastectomy or axillary radio-
therapy is needed after definitive pathology results become 
known. Examination of the specimen perioperatively 
resulted in cancelation of IORT in 10% of patients. Only 
6/270 patients in the IORT group received additional locore-
gional radiotherapy treatment, and 2/270 required a mastec-
tomy as a result of the definitive pathology outcome. Yet in 
93/295 patients, EB-APBI was canceled due to unforeseen 
pathology results. Nevertheless, all patients that started EB-
APBI completed the prescribed treatment (Fig. 1).
A strength of our study is that we included elderly 
patients, with a mean age of 68.5 years and 70% of patients 
aged ≥ 65 years. Elderly patients are underrepresented in 
randomized trials but are often suitable candidates for APBI 
due to favorable tumor features and conceivably they may 
benefit most from a less extensive treatment [25, 37].
A weakness of the current study is the treatment bias. 
Because of the nature of both treatments and the fact that 
IORT is only available in a limited number of centers, rand-
omization between treatments was not achievable nor did we 
have the capacity to collect a control group receiving con-
ventional WBI. Therefore, we chose to describe two cohorts 
receiving different types of ABPI using the same eligibil-
ity criteria, striving to create comparable groups. Given the 
fact that the two cohorts were collected in different centers, 
patient selection and surgical techniques may differ between 
centers. Therefore, firm conclusions regarding the differ-
ences between the two groups cannot be drawn.
The decision towards IORT, EB-ABPI, or even refrain-
ing from RT, will be influenced by patients’ preferences and 
tumor characteristics. Considering which aspects and out-
comes of treatment are important for each individual patient 
deserves great emphasis during patient consultation. Not 
only the acute effect of treatment, but also the effect on fibro-
sis, long-term toxicity, cosmesis, and health-related quality 
of life must be further investigated to facilitate patients and 
physicians in well-informed shared decision-making.
Conclusion
From literature, it can be concluded that although local con-
trol in elderly early breast cancer patients is acceptable with 
ABPI, the optimal treatment technique is yet to be defined. 
Despite the limitations of our study, we demonstrate that 
both IORT and EB-APBI are safe treatment modalities, with 
low acute toxicity and excellent compliance.
Fig. 4  Patient-reported fatigue and pain according to VAS scores 
per time point. The boxplots represent the median and first and third 
quartiles. The whiskers represent minimum and maximum scores, 
and the circles represent outliers
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Table 2  CTCAE v3.0
Adverse event Grade
1 2 3 4 5
Wound infection – Localized, local interven-
tion indicated
IV antibiotic, antifungal, 
or antiviral intervention 
indicated; interventional 
radiology or operative 
intervention indicated
Life-threatening conse-




Seroma Asymptomatic Symptomatic, medical 
intervention, or simple 
aspiration indicated
Symptomatic, interventional 
radiology, or operative 
intervention indicated
– –
Wound dehiscence Incisional separation 
of ≤ 25% of wound, 
no deeper than super-
ficial fascia
Incisional separation > 25% 
of wound with local care, 
asymptomatic hernia
Symptomatic hernia with-




wound closure or revision 
by operative intervention 
indicated, hospitalization, 
or hyperbaric oxygen 
indicated
Symptomatic hernia with 
evidence of strangulation, 
fascial disruption with 
evisceration, major recon-
struction flap, grafting, 
resection, or amputation 
indicated
Death




evacuation or aspiration 
indicated
Transfusion, interventional 
radiology, or operative 
intervention indicated.
Life-threatening conse-





– – Requiring transfusion of 
2 units non-autologous 
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